Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Asset Writedowns and Impairment (2024 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Asset Writedowns and Impairment for 2 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment fell 78.57% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $11.1 million, changed N/A, while the annual FY2025 figure was $5.8 million, 10.15% up from the prior year.
  • Asset Writedowns and Impairment hit $1.1 million in Q4 2025 for Barinthus Biotherapeutics, down from $4.7 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $5.3 million in Q4 2024 and bottomed at $1.1 million in Q4 2025.